X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
index medicus (426) 426
humans (421) 421
female (354) 354
male (352) 352
middle aged (339) 339
gastroenterology & hepatology (291) 291
adult (283) 283
aged (273) 273
genotype (162) 162
interferon (157) 157
antiviral agents - therapeutic use (151) 151
hepatitis c virus (140) 140
treatment outcome (140) 140
hepacivirus - genetics (137) 137
hepatocellular carcinoma (134) 134
virology (129) 129
hepatitis c, chronic - drug therapy (127) 127
ribavirin (118) 118
physics (110) 110
hepatitis c (107) 107
hepatocellular-carcinoma (104) 104
retrospective studies (104) 104
cinematography (100) 100
electrography (100) 100
electrophotography (100) 100
holography (100) 100
magnetography (100) 100
photography (100) 100
infection (97) 97
cirrhosis (90) 90
drug therapy, combination (90) 90
hepatitis (86) 86
japan (84) 84
interferon-alpha - therapeutic use (81) 81
therapy (81) 81
analysis (80) 80
hepatitis c, chronic - virology (80) 80
aged, 80 and over (78) 78
antiviral agents - administration & dosage (78) 78
liver cirrhosis (77) 77
care and treatment (72) 72
genetic aspects (71) 71
chronic hepatitis c (70) 70
hepatitis b virus (70) 70
hepatitis b virus - genetics (70) 70
multivariate analysis (67) 67
hepatology (66) 66
viral load (66) 66
ribavirin - therapeutic use (64) 64
genotypes (63) 63
health aspects (63) 63
risk factors (63) 63
medicine & public health (60) 60
oncology (60) 60
virus-infection (59) 59
young adult (59) 59
hcv (57) 57
lamivudine (56) 56
risk-factors (55) 55
liver cancer (54) 54
electricity (53) 53
gastroenterology (53) 53
hepatitis b, chronic - drug therapy (52) 52
time factors (52) 52
follow-up studies (51) 51
hepacivirus - drug effects (50) 50
prognosis (50) 50
alanine transaminase - blood (49) 49
colorectal surgery (48) 48
adolescent (47) 47
hepatitis b (47) 47
plus ribavirin (47) 47
ribavirin - administration & dosage (46) 46
rna, viral - blood (46) 46
antiviral agents - adverse effects (45) 45
interferons - therapeutic use (45) 45
mutation (45) 45
hepatitis c - drug therapy (43) 43
recombinant proteins (43) 43
hepatoma (41) 41
incidence (41) 41
interferon-alpha - administration & dosage (41) 41
surgical oncology (41) 41
chronic hepatitis (40) 40
cohort studies (40) 40
hepatitis c, chronic - complications (40) 40
combination therapy (39) 39
hepacivirus - isolation & purification (39) 39
lamivudine - therapeutic use (39) 39
trial (39) 39
hepatitis c - virology (38) 38
amino acid substitution (37) 37
diagnosis (37) 37
hepatitis b, chronic - virology (37) 37
liver (37) 37
liver neoplasms - pathology (37) 37
rna (37) 37
cancer (36) 36
original paper (36) 36
recurrence (36) 36
more...
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (1068) 1068
Japanese (98) 98
French (30) 30
German (26) 26
Korean (19) 19
Chinese (15) 15
Portuguese (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Journal of Gastroenterology, ISSN 0944-1174, 4/2017, Volume 52, Issue 4, pp. 512 - 519
Lenvatinib is an oral inhibitor of vascular endothelial growth factor receptor 1–3, fibroblast growth factor receptor 1–4, platelet-derived growth factor... 
E7080 | Medicine & Public Health | Tyrosine kinase inhibitor | Colorectal Surgery | Hepatology | Gastroenterology | Abdominal Surgery | Vascular endothelial growth factor inhibitor | Hepatocellular carcinoma | Lenvatinib | Surgical Oncology | MODIFIED RECIST | RESPONSE EVALUATION CRITERIA | SERUM | KINASE INHIBITOR | SORAFENIB | GASTROENTEROLOGY & HEPATOLOGY | ENDOTHELIAL GROWTH-FACTOR | Body Weight | Humans | Middle Aged | Male | Tomography, X-Ray Computed | Antineoplastic Agents - therapeutic use | Antineoplastic Agents - administration & dosage | Protein Kinase Inhibitors - adverse effects | Quinolines - administration & dosage | Carcinoma, Hepatocellular - diagnostic imaging | Young Adult | Carcinoma, Hepatocellular - drug therapy | Antineoplastic Agents - adverse effects | Phenylurea Compounds - adverse effects | Aged, 80 and over | Adult | Female | Liver Neoplasms - pathology | Drug Administration Schedule | Kaplan-Meier Estimate | Liver Neoplasms - drug therapy | Phenylurea Compounds - therapeutic use | Liver Neoplasms - diagnostic imaging | Disease Progression | Protein Kinase Inhibitors - administration & dosage | Phenylurea Compounds - administration & dosage | Protein Kinase Inhibitors - therapeutic use | Carcinoma, Hepatocellular - pathology | Aged | Quinolines - therapeutic use | Neoplasm Staging | Quinolines - adverse effects | Tyrosine | Complications and side effects | Medical research | Care and treatment | Medicine, Experimental | Hepatoma | Growth factors | Endothelium | Index Medicus | Original —Liver, Pancreas, and Biliary Tract
Journal Article
Journal of Gastroenterology, ISSN 0944-1174, 2015, Volume 50, Issue 3, pp. 350 - 360
Journal Article
Journal of Gastroenterology, ISSN 0944-1174, 5/2014, Volume 49, Issue 5, pp. 941 - 953
Efficacy of available therapies for patients with HCV who have previously failed treatment is limited. Two Phase III, open-label trials in Japan investigated... 
Simeprevir | Chronic hepatitis C | Medicine & Public Health | Colorectal Surgery | Treatment-experienced | Hepatology | Gastroenterology | Abdominal Surgery | Surgical Oncology | Sustained virologic response | TMC435 | VIRUS-INFECTION | TELAPREVIR | CHRONIC HEPATITIS-C | RANDOMIZED-TRIAL | SUSTAINED VIROLOGICAL RESPONSE | PROTEASE INHIBITOR | INTERFERON-ALPHA-2B PLUS RIBAVIRIN | PEGYLATED INTERFERON | BOCEPREVIR | RETREATMENT | GASTROENTEROLOGY & HEPATOLOGY | Recombinant Proteins - therapeutic use | Recurrence | Humans | Middle Aged | Hepacivirus - genetics | Polyethylene Glycols - adverse effects | Male | Recombinant Proteins - adverse effects | Polyethylene Glycols - therapeutic use | Young Adult | Ribavirin - administration & dosage | Adult | Female | Drug Therapy, Combination | Hepacivirus - isolation & purification | Drug Administration Schedule | Antiviral Agents - therapeutic use | Japan | Ribavirin - therapeutic use | Interferon-alpha - therapeutic use | Genotype | Hepatitis C, Chronic - drug therapy | Antiviral Agents - administration & dosage | Polyethylene Glycols - administration & dosage | Recombinant Proteins - administration & dosage | Interferon-alpha - administration & dosage | Sulfonamides - therapeutic use | Ribavirin - adverse effects | Antiviral Agents - adverse effects | Heterocyclic Compounds, 3-Ring - administration & dosage | Heterocyclic Compounds, 3-Ring - adverse effects | Heterocyclic Compounds, 3-Ring - therapeutic use | Sulfonamides - adverse effects | Aged | Interferon-alpha - adverse effects | Sulfonamides - administration & dosage | Medical research | Care and treatment | Medicine, Experimental | Genetic aspects | Interferon | Hepatitis C | Hepatitis C virus | Index Medicus
Journal Article
Nihon rinsho. Japanese journal of clinical medicine, ISSN 0047-1852, 12/2015, Volume 73, pp. 23 - 29
Journal Article
Nihon rinsho. Japanese journal of clinical medicine, ISSN 0047-1852, 12/2015, Volume 73 Suppl 9, p. 23
Journal Article
Hepatology, ISSN 0270-9139, 03/2012, Volume 55, Issue 3, pp. 742 - 748
Journal Article
Journal Article
Journal of Gastroenterology, ISSN 0944-1174, 4/2018, Volume 53, Issue 4, pp. 566 - 575
Once-daily, orally administered, co-formulated glecaprevir (NS3/4A protease inhibitor) and pibrentasvir (NS5A inhibitor) (G/P) demonstrated pangenotypic... 
Pibrentasvir | Cirrhosis | Medicine & Public Health | Glecaprevir | Colorectal Surgery | Hepatology | Gastroenterology | Renal failure | Abdominal Surgery | Special population | Surgical Oncology | PLUS RIBAVIRIN | SOFOSBUVIR | CHRONIC HEPATITIS-C | OPEN-LABEL | TREATMENT-NAIVE | PHASE-3 TRIAL | DACLATASVIR | GASTROENTEROLOGY & HEPATOLOGY | BURDEN | EPIDEMIOLOGY | Quinoxalines - adverse effects | Humans | Middle Aged | Hepacivirus - genetics | Hepatitis C, Chronic - virology | Male | RNA, Viral - blood | Hepatitis C, Chronic - complications | Young Adult | Treatment Failure | Adult | Female | Renal Insufficiency - complications | Benzimidazoles - adverse effects | Drug Therapy, Combination | Benzimidazoles - therapeutic use | Quinoxalines - therapeutic use | Hepacivirus - isolation & purification | Antiviral Agents - therapeutic use | Genotype | Treatment Outcome | Hepatitis C, Chronic - drug therapy | Sulfonamides - therapeutic use | Antiviral Agents - adverse effects | Adolescent | Sulfonamides - adverse effects | Aged | Sustained Virologic Response | Medical research | Protease inhibitors | Proteases | Analysis | Medicine, Experimental | Genetic aspects | Biological response modifiers | Hepatitis C virus | Health aspects | Liver cirrhosis | Kidneys | Hemodialysis | Oral administration | Chronic infection | Interferon | Ribonucleic acid--RNA | Patients | Glomerular filtration rate | Kidney transplantation | Index Medicus | Original —Liver, Pancreas, and Biliary Tract
Journal Article
Journal of Gastroenterology, ISSN 0944-1174, 4/2017, Volume 52, Issue 4, pp. 520 - 533
Elbasvir (EBR) in combination with grazoprevir (GZR) has demonstrated efficacy in patients with hepatitis C virus (HCV) infections in trials primarily... 
Therapy | Medicine & Public Health | Colorectal Surgery | Hepatology | Gastroenterology | Abdominal Surgery | Genotype | Efficacy | Clinical trial | Surgical Oncology | Sustained virologic response | MK-8742 | MK-5172 | OPEN-LABEL | RIBAVIRIN | TRIAL | TREATMENT-NAIVE | HEPATITIS-C VIRUS | CIRRHOSIS | GENOTYPE 1 INFECTION | INHIBITOR | GASTROENTEROLOGY & HEPATOLOGY | Quinoxalines - adverse effects | Humans | Middle Aged | Drug Resistance, Viral | Hepacivirus - genetics | Hepatitis C, Chronic - virology | Imidazoles - administration & dosage | Benzofurans - administration & dosage | Male | RNA, Viral - blood | Benzofurans - blood | Hepatitis C, Chronic - complications | Quinoxalines - blood | Young Adult | Aged, 80 and over | Adult | Female | Imidazoles - therapeutic use | Drug Therapy, Combination | Quinoxalines - therapeutic use | Hepacivirus - drug effects | Hepacivirus - isolation & purification | Liver Cirrhosis - drug therapy | Benzofurans - therapeutic use | Double-Blind Method | Drug Administration Schedule | Quinoxalines - administration & dosage | Administration, Oral | Antiviral Agents - blood | Antiviral Agents - therapeutic use | Imidazoles - adverse effects | Treatment Outcome | Hepatitis C, Chronic - drug therapy | Antiviral Agents - administration & dosage | Benzofurans - adverse effects | Hepatitis C, Chronic - blood | Imidazoles - blood | Liver Cirrhosis - virology | Antiviral Agents - adverse effects | Aged | Sustained Virologic Response | Medicine, Experimental | Clinical trials | Medical research | Hepatitis C virus | Health aspects | Index Medicus | Original —Liver, Pancreas, and Biliary Tract
Journal Article
Journal of Gastroenterology, ISSN 0944-1174, 4/2018, Volume 53, Issue 4, pp. 557 - 565
The once-daily, all oral, RBV-free, pangenotypic direct-acting anti-viral regimen consisting of co-formulated NS3/4A protease inhibitor glecaprevir and NS5A... 
Medicine & Public Health | Colorectal Surgery | Hepatology | Gastroenterology | Abdominal Surgery | Glecaprevir/pibrentasvir | Hepatitis C virus | Surgical Oncology | Direct-acting antivirals | ASIA | PHASE-3 TRIAL | RIBAVIRIN | COMPENSATED CIRRHOSIS | COMBINATION | GASTROENTEROLOGY & HEPATOLOGY | BURDEN | EPIDEMIOLOGY | Quinoxalines - adverse effects | Anilides - therapeutic use | Age Distribution | Humans | Middle Aged | Hepacivirus - genetics | Hepatitis C, Chronic - virology | Male | RNA, Viral - blood | Hepatitis C, Chronic - complications | Quinoxalines - blood | Sulfonamides - blood | Aged, 80 and over | Ritonavir - therapeutic use | Adult | Female | Benzimidazoles - adverse effects | Drug Therapy, Combination | Benzimidazoles - blood | Benzimidazoles - therapeutic use | Quinoxalines - therapeutic use | Hepacivirus - isolation & purification | Liver Cirrhosis - drug therapy | Drug Administration Schedule | Antiviral Agents - blood | Antiviral Agents - therapeutic use | Viral Nonstructural Proteins - genetics | Liver Cirrhosis - blood | Hepatitis C, Chronic - drug therapy | Hepatitis C, Chronic - blood | Macrocyclic Compounds - therapeutic use | Liver Cirrhosis - virology | Sulfonamides - therapeutic use | Antiviral Agents - adverse effects | Sulfonamides - adverse effects | Aged | Sustained Virologic Response | Carbamates - therapeutic use | Drug Combinations | Virus diseases | Medical research | Protease inhibitors | Proteases | Medicine, Experimental | Genetic aspects | Health aspects | Liver cirrhosis | Cirrhosis | Antiviral agents | Ritonavir | Chronic infection | Proteinase inhibitors | Hepatitis C | Patients | Genotypes | Index Medicus | Glecaprevir | pibrentasvir | Original —Liver, Pancreas, and Biliary Tract
Journal Article
Journal Article